4D Molecular Therapeutics (4DMT) announced a research and development collaboration with the Casey Eye Institute and the Oregon National Primate Research Center at Oregon Health & Science University (OHSU). The collaboration will combine the complementary expertise of 4D Molecular Therapeutics with the Casey Eye Institute and the Oregon National Primate Research Center to identify and develop gene therapies for degenerative retinal diseases.
“I’m delighted with the potential of this exciting partnership between 4DMT and OHSU’s Casey Eye Institute and the Oregon National Primate Research Center. This collaboration will accelerate translation of new treatments for currently incurable retinal diseases,” Peter Francis, SVP Clinical, Translational R&D, Program Leader, Ophthalmology Therapeutic Area of 4D Molecular Therapeutics, said in a company news release.
Under the terms of the agreement, 4DMT will provide research access to its proprietary vector and gene therapy product technology, development expertise and manufacturing capabilities. Casey Eye Institute and ONPRC will provide access to its researchers and resources for the inception, design and conduct of joint research programs. 4DMT retains all patent and commercial rights to its proprietary AAV technology.
David Wilson, MD, Director of OHSU’s Casey Eye Institute, commented, “We are excited to work with Peter Francis and his ophthalmology team at 4D. Their novel Therapeutic Vector Evolution AAV platform holds huge promise for patients with inherited retinal dystrophies and related conditions.”